RT Journal Article SR Electronic T1 Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.05.28.20115667 DO 10.1101/2020.05.28.20115667 A1 Philip A. Mudd A1 Jeremy Chase Crawford A1 Jackson S. Turner A1 Aisha Souquette A1 Daniel Reynolds A1 Diane Bender A1 James P. Bosanquet A1 Nitin J. Anand A1 David A. Striker A1 R. Scott Martin A1 Adrianus C. M. Boon A1 Stacey L. House A1 Kenneth E. Remy A1 Richard S. Hotchkiss A1 Rachel M. Presti A1 Jane A. O’Halloran A1 William G. Powderly A1 Paul G. Thomas A1 Ali H. Ellebedy YR 2020 UL http://medrxiv.org/content/early/2020/05/30/2020.05.28.20115667.abstract AB Coronavirus disease 2019 (COVID-19) is characterized by a high incidence of acute respiratory failure. The underlying immunopathology of that failure and how it compares to other causes of severe respiratory distress, such as influenza virus infection, are not fully understood. Here we addressed this by developing a prospective observational cohort of COVID-19 and influenza subjects with varying degrees of disease severity and assessing the quality and magnitude of their immune responses at the cellular and protein level. Additionally, we performed single-cell RNA transcriptional profiling of peripheral blood mononuclear cells from select subjects. The cohort consists of 79 COVID-19 subjects, 26 influenza subjects, and 15 control subjects, including 35 COVID-19 and 7 influenza subjects with acute respiratory failure. While COVID-19 subjects exhibited largely equivalent or greater activated lymphocyte counts compared to influenza subjects, they had fewer monocytes and lower surface HLA-class II expression on monocytes compared to influenza subjects and controls. At least two distinct immune profiles were observed by cytokine levels in severe COVID-19 patients: 3 of 71 patients were characterized by extreme inflammation, with greater than or equal to ∼50% of the 35 cytokines measured greater than 2 standard deviations from the mean level of other severe patients (both influenza and COVID-19); the other immune profile, which characterized 68 of 71 subjects, had a mixed inflammatory signature, where 28 of 35 cytokines in COVID-19 patients had lower mean cytokine levels, though not all were statistically significant. Only 2 cytokines were higher in COVID-19 subjects compared to influenza subjects (IL-6 and IL-8). Influenza and COVID-19 patients could be distinguished statistically based on cytokine module expression, particularly after controlling for the significant effects of age on cytokine expression, but again with lower levels of most cytokines in COVID-19 subjects. Further, high circulating levels of IL-1RA and IL-6 were associated with increased odds of intubation in the combined influenza and COVID-19 cohort [OR = 3.93 and 4.30, respectively] as well as among only COVID-19 patients. Single cell transcriptional profiling of COVID-19 and influenza subjects with respiratory failure identified profound suppression in type I and type II interferon signaling in COVID-19 patients across multiple clusters. In contrast, COVID-19 cell clusters were enriched for alterations in metabolic, stress, and apoptotic pathways. These alterations were consistent with an increased glucocorticoid response in COVID-19 patients compared to influenza. When considered across the spectrum of innate and adaptive immune profiles, the immune pathologies underlying severe influenza and COVID-19 are substantially distinct. The majority of COVID-19 patients with acute respiratory failure do not have a cytokine storm phenotype but instead exhibit profound type I and type II IFN immunosuppression when compared to patients with acute influenza. Upregulation of a small number of inflammatory mediators, including IL-6, predicts acute respiratory failure in both COVID-19 and influenza patients.Competing Interest StatementA.H.E. is a consultant for Inbios and Fimbrion Therapeutics. The Ellebedy laboratory received funding under sponsored research agreements from Emergent BioSolutions. All other authors declare that they do not have any commercial interests or other associations that pose a conflict of interest with the published work.Funding StatementThis work was supported by a grant from the Barnes Jewish Hospital Foundation to PAM, by grants NIAID R21 AI139813, U01 AI141990, Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051, and NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C to AHE and by the St. Jude Center of Excellence for Influenza Research and Surveillance (HHSN272201400006C), R01AI121832, and ALSAC to PGT. The COVID-19 clinical cohort reported in this publication was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Washington University in Saint Louis School of Medicine Institutional Review Board Approval #s 202003085, 201707160, 201801209, 201808171, 201710220, 201808115 and 201910011. Missouri Baptist Medical Center Institutional Review Board Approval #1132.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw flow cytometry and cytokine data can be found in Supplementary Tables 1 and 2, respectively. Single cell gene expression sequences have been uploaded to the NCBI Short Read Archive under BioProject ID PRJNA630932.